These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24039406)

  • 1. Long-acting preparations of exenatide.
    Cai Y; Wei L; Ma L; Huang X; Tao A; Liu Z; Yuan W
    Drug Des Devel Ther; 2013; 7():963-70. PubMed ID: 24039406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.
    Syed YY; McCormack PL
    Drugs; 2015 Jul; 75(10):1141-52. PubMed ID: 26071140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.
    Liu B; Dong Q; Wang M; Shi L; Wu Y; Yu X; Shi Y; Shan Y; Jiang C; Zhang X; Gu T; Chen Y; Kong W
    Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1474-9. PubMed ID: 21048339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release exenatide (Bydureon) for type 2 diabetes.
    Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
    [No Abstract]   [Full Text] [Related]  

  • 6. [Twice-daily and weekly exenatide: Clinical profile of two pioneer formulations in incretin therapy].
    Lecube A; Bueno M; Suárez X
    Med Clin (Barc); 2014; 143 Suppl 2():23-7. PubMed ID: 25326840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
    J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
    Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
    Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
    Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
    Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide: AC 2993, AC002993, AC2993A, exendin 4, LY2148568.
    Drugs R D; 2004; 5(1):35-40. PubMed ID: 14725490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
    Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
    J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
    Li H; Xu J; Fan X
    J Pharmacol Sci; 2015 Feb; 127(2):170-80. PubMed ID: 25727954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
    Calara F; Taylor K; Han J; Zabala E; Carr EM; Wintle M; Fineman M
    Clin Ther; 2005 Feb; 27(2):210-5. PubMed ID: 15811484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide Once Weekly: A Review of Pharmacology and Treatment Considerations in Type 2 Diabetes.
    Brunton S; Davidson JA
    Clin Ther; 2016 Mar; 38(3):582-94. PubMed ID: 26926319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
    Anderson ZL; Clements JN
    JAAPA; 2014 Jun; 27(6):44-6. PubMed ID: 24853156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.